According to Gemini, Merck isn't safe and dry just because of Keytruda Qlex, it'll rather slow down their decline of revenues and SP (but companies are always about maximizing profits).
Conclusion and Outlook
Qlex will not completely solve the problem of expiring exclusivity, but it prevents a freefall in stock price and revenue. It has bought Merck a window of time deep into the 2030s to further expand its own pipeline (e.g., through ADC cancer therapies OR BY MAYBE BUYING OUT CERTAIN COMPANIES).
"Keytruda Qlex is the centerpiece of Merck’s (MSD) strategy to cushion the massive "patent cliff" looming in 2028. As of March 2026, we already have concrete facts regarding its status and strategic implementation.
Here is the analysis of the situation:
1. Approval Status: Already Granted
If you were waiting for the initial approval, that hurdle has already been cleared.
* FDA Approval: The U.S. Food and Drug Administration (FDA) approved Keytruda Qlex (the subcutaneous formulation of pembrolizumab in combination with berahyaluronidase alfa-pmph) on September 19, 2025.
* Indications: The approval covers nearly all solid tumor indications for which the IV (intravenous) version is approved. Since early 2026, successive expansions for specific combination therapies (e.g., in ovarian cancer) have also been authorized.
2. Can Qlex Solve the Patent Problem?
It is not a "silver bullet" that will save all revenue, but it serves as a very powerful "revenue bridge" mechanism.
* The Strategy (Product Hopping): Merck aims to transition approximately 30% to 40% of patients to the subcutaneous version (Qlex) before the main patents for the IV version expire at the end of 2028.
* Patent Protection: While the patents for IV infusion will lapse in 2028/2029—allowing biosimilars to flood the market—the Qlex formulation is protected by new patents. Experts estimate this protection could last until 2041.
* Merck’s Advantage: Once a patient has switched to the more convenient injection (1–2 minutes administration), it becomes significantly harder for biosimilar manufacturers to reclaim that market share with an older IV version (30–60 minutes infusion).
3. What are the Prospects?
The chances that Qlex will significantly dampen the revenue decline are high, though there are limitations:
| Factor | Impact on Success |
|---|---|
| Patient Convenience | Very High. The injection takes only 1–2 minutes compared to a lengthy infusion. This saves time in clinics and is far more comfortable for patients. |
| Costs & IRA | Challenging. Due to the Inflation Reduction Act in the U.S., Keytruda will likely be subject to government price negotiations starting in 2028, which will squeeze margins regardless of whether it is IV or Qlex. |
| Biosimilar Competition | Inevitable. From 2028, IV biosimilars (e.g., from Sandoz or Samsung Bioepis) will enter the market. Qlex can only protect the portion of the market that has been actively transitioned. |
4. Conclusion and Outlook
Qlex will not completely solve the problem of expiring exclusivity, but it prevents a freefall in stock price and revenue. It has bought Merck a window of time deep into the 2030s to further expand its own pipeline (e.g., through ADC cancer therapies).
The Next Phase: Over the next two years (2026–2028), the decisive factor will be how aggressively Merck drives the "switching" process within clinical practice."
Conclusion and Outlook
Qlex will not completely solve the problem of expiring exclusivity, but it prevents a freefall in stock price and revenue. It has bought Merck a window of time deep into the 2030s to further expand its own pipeline (e.g., through ADC cancer therapies OR BY MAYBE BUYING OUT CERTAIN COMPANIES).
"Keytruda Qlex is the centerpiece of Merck’s (MSD) strategy to cushion the massive "patent cliff" looming in 2028. As of March 2026, we already have concrete facts regarding its status and strategic implementation.
Here is the analysis of the situation:
1. Approval Status: Already Granted
If you were waiting for the initial approval, that hurdle has already been cleared.
* FDA Approval: The U.S. Food and Drug Administration (FDA) approved Keytruda Qlex (the subcutaneous formulation of pembrolizumab in combination with berahyaluronidase alfa-pmph) on September 19, 2025.
* Indications: The approval covers nearly all solid tumor indications for which the IV (intravenous) version is approved. Since early 2026, successive expansions for specific combination therapies (e.g., in ovarian cancer) have also been authorized.
2. Can Qlex Solve the Patent Problem?
It is not a "silver bullet" that will save all revenue, but it serves as a very powerful "revenue bridge" mechanism.
* The Strategy (Product Hopping): Merck aims to transition approximately 30% to 40% of patients to the subcutaneous version (Qlex) before the main patents for the IV version expire at the end of 2028.
* Patent Protection: While the patents for IV infusion will lapse in 2028/2029—allowing biosimilars to flood the market—the Qlex formulation is protected by new patents. Experts estimate this protection could last until 2041.
* Merck’s Advantage: Once a patient has switched to the more convenient injection (1–2 minutes administration), it becomes significantly harder for biosimilar manufacturers to reclaim that market share with an older IV version (30–60 minutes infusion).
3. What are the Prospects?
The chances that Qlex will significantly dampen the revenue decline are high, though there are limitations:
| Factor | Impact on Success |
|---|---|
| Patient Convenience | Very High. The injection takes only 1–2 minutes compared to a lengthy infusion. This saves time in clinics and is far more comfortable for patients. |
| Costs & IRA | Challenging. Due to the Inflation Reduction Act in the U.S., Keytruda will likely be subject to government price negotiations starting in 2028, which will squeeze margins regardless of whether it is IV or Qlex. |
| Biosimilar Competition | Inevitable. From 2028, IV biosimilars (e.g., from Sandoz or Samsung Bioepis) will enter the market. Qlex can only protect the portion of the market that has been actively transitioned. |
4. Conclusion and Outlook
Qlex will not completely solve the problem of expiring exclusivity, but it prevents a freefall in stock price and revenue. It has bought Merck a window of time deep into the 2030s to further expand its own pipeline (e.g., through ADC cancer therapies).
The Next Phase: Over the next two years (2026–2028), the decisive factor will be how aggressively Merck drives the "switching" process within clinical practice."
3
